Tesofensine: selected references HeartPep literature library, reviewed 2026-11-09 https://heartpep.com/us/research/library/tesofensine 1. Astrup A, Madsbad S, Breum L, et al. (2008). Effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trial The Lancet. DOI: https://doi.org/10.1016/S0140-6736(08)61525-1 PMID: 18950853 Source: https://pubmed.ncbi.nlm.nih.gov/18950853/ Verification: Abstract / bibliographic record. 2. The Lancet, no named author listed in PubMed (2013). Expression of concern--effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trial The Lancet. DOI: https://doi.org/10.1016/S0140-6736(13)60778-3 PMID: 23561987 Source: https://pubmed.ncbi.nlm.nih.gov/23561987/ Verification: Abstract / bibliographic record. 3. Astrup A, Madsbad S, Breum L, et al. (2013). Under-reporting of adverse effects of tesofensine The Lancet. DOI: https://doi.org/10.1016/S0140-6736(13)61563-9 PMID: 23849924 Source: https://pubmed.ncbi.nlm.nih.gov/23849924/ Verification: Abstract / bibliographic record. 4. Investigator-submitted UMIN-CTR record; principal investigator Reyes-Garcia JG (2024). Efficacy and safety of tesofensine for the treatment of obesity in adults: a phase 3 randomized controlled study UMIN Clinical Trials Registry. Source: https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000061771 Verification: Abstract / bibliographic record. These are selected background references, not evidence that a HeartPep product or batch matches a studied preparation. Cite and assess the original papers.